# Project Intake Questionnaire — Cyprus IP Box Matter — Template

| Field | Value |
|---|---|
| Document type | Structured intake form filled at Stage 1.1 (6-question screen) + Stage 1.2 (90-min discovery call) per [[stages]] |
| When used | Every new matter, before S1 engagement letter is signed. Output drives Creatio record + `/api/matters` skeleton + project folder structure + Track A/B routing on `/calculator` + required-evidence baseline for client-document analysis (Sprint 1.7 LLM module) |
| Owner role | Sales lead (Section A); Middle + AS (Sections B–E on discovery call); PM stores filled form in matter folder before G4-engagement sign |
| Gate status | Section A → G0 routing (Track decision); Section C → G2 schema pre-fill for engine; full form → G4 engagement sign-off |
| Related stages | Phase 0 Stage 0.1 (Track B path), Phase 1 Stage 1.1 (inbound qualification), Phase 1 Stage 1.2 (discovery + S1 engagement) |
| Office 365 mirror | `/Interlegal — Cyprus IP Box/Matters/<matter-id>/00-intake-questionnaire.docx` |

---

**Project Intake Questionnaire**

Matter ID: {{MATTER_ID}}
Intake date: {{INTAKE_DATE_ISO}}
Sales lead: {{SALES_LEAD_NAME}} · Middle on call: {{SENIOR_NAME}} · AS attended: ☐ Yes ☐ No
Discovery call duration: {{CALL_DURATION_MIN}} min · Recording stored: ☐ Yes ☐ No · Location: {{CALL_LOCATION_OR_LINK}}

---

## Section A — Inbound 6-question screen (Stage 1.1; pre-call qualification)

Filled by Sales lead from inbound form / first contact. **All six required before proceeding.**

| # | Question | Answer | Routing impact |
|---|---|---|---|
| A1 | **Type of IP.** Patent / copyrighted software / utility model / plant variety / orphan drug — or marketing/brand only? | {{IP_TYPE}} | If "marketing/brand only" → NQL (not qualifying lead). Decline. |
| A2 | **Current jurisdiction of the IP.** Where is the asset legally owned today? | {{IP_CURRENT_JURISDICTION}} | If UA → standard inbound transfer path. If non-EU + non-UA → tax-exit screen needed. |
| A3 | **Annual revenue from the IP** (or potential, if pre-revenue). | EUR {{IP_ANNUAL_REVENUE}} | If < EUR 80k → NQL (cost-to-serve unjustified). Decline. |
| A4 | **Group consolidated revenue** (Pillar 2 screen). Total revenue of ultimate-parent group. | EUR {{GROUP_CONSOL_REVENUE}} | If ≥ EUR 750M → escalate to Partner; Pillar 2 likely cancels IP Box benefit. |
| A5 | **UA exposure.** Is any group entity UA-tax-resident? Any UA operations beyond R&D? | {{UA_EXPOSURE_DESC}} | Triggers UA exit-tax pre-screen + DAC7 + reputational review. |
| A6 | **Timeline horizon.** When does the client need first claim filed? | {{TIMELINE_HORIZON}} | If < 4 months → infeasible (typical 5-month cycle); decline or extend expectation. |

**Screen verdict (Sales lead + AS):** ☐ Pass → proceed to discovery call · ☐ NQL → decline with reason: {{NQL_REASON}}

---

## Section B — Track routing (Stage 1.1 / G0)

| # | Question | Answer | Routing |
|---|---|---|---|
| B1 | **Existing Cyprus Ltd?** Does the client already operate a Cyprus-incorporated entity for this asset? | ☐ Yes ☐ No ☐ Unknown | Yes → Track B (Phase 0 S0 Diagnostic required). No → Track A. Unknown → schedule clarification call before proceeding. |
| B2 | **If Track B (existing Cyprus Ltd):** Cyprus Ltd registration number, registered office, current corporate-services provider | {{CY_LTD_REG_NO}} / {{CY_LTD_OFFICE}} / {{CY_LTD_CSP}} | Inputs to Phase 0 Stage 0.1 5-area diagnostic per [[ADR-007]] + [[15-existing-company-diagnostic]] |
| B3 | **If Track B:** is the existing entity carrying any historical IP Box claim (under old regime or current)? | ☐ Yes ☐ No ☐ Don't know | Yes → out of scope (refer to historical-claims-counsel); No → proceed. |
| B4 | **If Track B:** can the ex-provider release accounting + corporate filings in cooperative manner? | ☐ Yes ☐ No ☐ Negotiating | No → recommend Track A new-setup instead. |

**Routing decision:** ☐ Track A · ☐ Track B (Phase 0 required) · ☐ Pending (clarification call scheduled {{DATE}})

---

## Section C — S1 deep intake (Stage 1.2; on 90-min discovery call)

Fill jointly with client on the discovery call. Every field is required for G4 engagement sign-off; missing items flagged for follow-up before signature.

### C1. Client identity + UBO chain

- **Legal name:** {{CLIENT_LEGAL_NAME}}
- **Jurisdiction of incorporation:** {{CLIENT_JURISDICTION}}
- **Registered address:** {{CLIENT_REGISTERED_ADDRESS}}
- **Primary contact:** {{CLIENT_PRIMARY_CONTACT_NAME}} · {{CLIENT_PRIMARY_CONTACT_ROLE}} · {{CLIENT_PRIMARY_CONTACT_EMAIL}} · {{CLIENT_PRIMARY_CONTACT_PHONE}}
- **UBO chain (≥10% beneficial owners with country of residence):** {{UBO_CHAIN_NARRATIVE}}
- **Sanctioned-UBO check passed:** ☐ Yes ☐ Pending — date due {{SANCTIONS_CHECK_DATE}}
- **Group structure diagram provided:** ☐ Yes ☐ No — TBC by {{DATE}}

### C2. Asset description

- **Asset working name:** {{ASSET_NAME}}
- **Qualifying head proposed (per Cyprus IT(LM)IRR):** ☐ copyrighted software ☐ patent ☐ utility model ☐ plant variety ☐ orphan drug ☐ unsure
- **Description (one paragraph; what does it do, who uses it):** {{ASSET_DESCRIPTION}}
- **Ownership chain (current legal owner → all prior transfers / assignments):** {{OWNERSHIP_CHAIN}}
- **R&D history (when started, who built, contractor vs employee split):** {{RD_HISTORY}}
- **Registration / publication date** (patent / copyright registration / first commit / first sale): {{REGISTRATION_DATE}}
- **Existing assignment deeds / contractor IP-assignment clauses available:** ☐ Yes ☐ Partial ☐ No

### C3. Financials

| Metric | Cumulative since inception | Current annual | Projection year +5 |
|---|---|---|---|
| Qualifying Expenditure (QE) | EUR {{QE_CUMULATIVE}} | — | — |
| Overall Expenditure (OE) | EUR {{OE_CUMULATIVE}} | — | — |
| Acquisition cost (if any) | EUR {{ACQ_COST}} | — | — |
| Related-party R&D | EUR {{RELATED_PARTY_RD}} | EUR {{RELATED_PARTY_RD_ANNUAL}} | EUR {{RELATED_PARTY_RD_Y5}} |
| Overall Income (OI) from the IP | — | EUR {{OI_CURRENT_ANNUAL}} | EUR {{OI_Y5}} |
| Group consolidated revenue | — | EUR {{GROUP_CONSOL_CURRENT}} | EUR {{GROUP_CONSOL_Y5}} |

- **Currency confirmed:** ☐ EUR ☐ Other ({{CURRENCY}}; conversion date {{FX_DATE}})
- **Source of figures:** ☐ Audited financials ☐ Management accounts ☐ Founder estimate

### C4. Substance baseline (if any Cyprus presence exists today)

Filled per 12-criteria scorecard from [[04-substance-gap-analysis]]:

| # | Criterion | Status | Gap notes |
|---|---|---|---|
| C-1 | Office lease in Cyprus | ☐ Yes ☐ No ☐ Planned | {{C1_NOTE}} |
| C-2 | Office signage | ☐ Yes ☐ No ☐ Planned | {{C2_NOTE}} |
| C-3 | Utilities + insurance in company name | ☐ Yes ☐ No ☐ Planned | {{C3_NOTE}} |
| C-4 | ≥1 Cyprus-resident director with tax cert | ☐ Yes ☐ No ☐ Planned | {{C4_NOTE}} |
| C-5 | Director documented decision authority | ☐ Yes ☐ No ☐ Planned | {{C5_NOTE}} |
| C-6 | ≥1 R&D employee in Cyprus on qualifying IP | ☐ Yes ☐ No ☐ Planned | {{C6_NOTE}} |
| C-7 | Cyprus social insurance + GHS active | ☐ Yes ☐ No ☐ Planned | {{C7_NOTE}} |
| C-8 | Board meeting held physically in Cyprus last quarter | ☐ Yes ☐ No ☐ N/A (pre-incorp) | {{C8_NOTE}} |
| C-9 | Board minutes signed in Cyprus | ☐ Yes ☐ No ☐ N/A | {{C9_NOTE}} |
| C-10 | Decision-making evidence per major action | ☐ Yes ☐ No ☐ N/A | {{C10_NOTE}} |
| C-11 | Communications use Cyprus channels (@cy-domain, +357) | ☐ Yes ☐ No ☐ Planned | {{C11_NOTE}} |
| C-12 | Bookkeeping by ICPAC member | ☐ Yes ☐ No ☐ Planned | {{C12_NOTE}} |

**Baseline score:** {{SUBSTANCE_BASELINE_SCORE}} / 12 · Threshold for IP Box claim is ≥ 9.

### C5. Cross-border / transfer pricing

- **Related-party flows (intra-group services / licences / R&D contracts):** {{RELATED_PARTY_FLOWS_DESC}}
- **Existing TP documentation:** ☐ Master file ☐ Local file ☐ Benchmarks ☐ None
- **Cost-plus or other markup model with related parties:** ☐ Cost-plus ___% ☐ Other: {{TP_MODEL}} ☐ N/A (no related-party flows)
- **DEMPE allocation pre-assessment (Development / Enhancement / Maintenance / Protection / Exploitation owner per function):** {{DEMPE_NARRATIVE}}

### C6. Hard-blocker pre-screen (7 items per A003 Block P.6)

Any **one** tick → matter not claim-ready until cleared. Engine returns `not_claim_ready` regardless of nexus arithmetic.

- ☐ **HB-1 Pillar 2 exposure** (group consol revenue ≥ EUR 750M)
- ☐ **HB-2 IP Box conflict** with another regime / state aid (e.g. Cyprus tonnage / shipping; another country's IP box already claimed)
- ☐ **HB-3 Ownership chain broken** (missing assignment deed, contested ownership, contractor without IP clause)
- ☐ **HB-4 DAC6 mandatory disclosure trigger** unresolved
- ☐ **HB-5 Sanctioned-UBO** (verified hit on EU / OFAC / UK sanctions)
- ☐ **HB-6 Adverse audit history** on prior corporate filings (relevant for Track B)
- ☐ **HB-7 UA exit-tax exposure** unaddressed (asset transferred from UA without exit-tax clearance)

**Cleared all 7:** ☐ Yes — date {{HB_CLEAR_DATE}} ☐ No — open items: {{HB_OPEN_ITEMS}}

### C7. G6 trigger pre-check (per [[ADR-005]])

Any of the following triggers G6 external second-review during execution (does not block engagement, but flags scope + fee adjustment):

- ☐ Qualifying profit projected ≥ EUR 5M
- ☐ Annual tax saving projected ≥ EUR 500k
- ☐ Related-party R&D ≥ EUR 5M cumulative
- ☐ IP asset transferred into structure ≤ 5 years from claim
- ☐ Non-EU UBO with ≥ 25% stake
- ☐ Pillar 2 threshold approached (group ≥ EUR 500M)
- ☐ SaaS revenue with unclear allocation between IP vs non-IP components
- ☐ No clean / audited accounting history
- ☐ Existing Cyprus company verdict not Green (Track B Amber/Red)

**G6 likely required:** ☐ Yes ☐ No — note for fee adjustment + external counsel sourcing

### C8. Documentation provided / outstanding

Initial document pack — what client has supplied at intake. Drives [[03-ip-fingerprint-memo]] + [[04-substance-gap-analysis]] preparation and feeds the required-evidence baseline for LLM document analysis (Sprint 1.7).

| Category | Provided | Outstanding | Due date |
|---|---|---|---|
| Corporate (cert of incorp, M&A, register, board minutes) | {{CORP_PROVIDED}} | {{CORP_OUTSTANDING}} | {{CORP_DUE}} |
| Financial (audit reports, management accounts) | {{FIN_PROVIDED}} | {{FIN_OUTSTANDING}} | {{FIN_DUE}} |
| IP ownership chain (assignment deeds, registration certs, contractor invoices + IP clauses) | {{IP_PROVIDED}} | {{IP_OUTSTANDING}} | {{IP_DUE}} |
| R&D records (git history, time logs, employment contracts, contractor SoWs) | {{RD_PROVIDED}} | {{RD_OUTSTANDING}} | {{RD_DUE}} |
| Substance (lease, utilities, payroll, board minutes Cyprus, directors' tax certs) | {{SUB_PROVIDED}} | {{SUB_OUTSTANDING}} | {{SUB_DUE}} |
| Cross-border (intra-group agreements, TP documentation, related-party flows) | {{CB_PROVIDED}} | {{CB_OUTSTANDING}} | {{CB_DUE}} |
| Tax history (last 3y tax returns, any prior rulings, audit correspondence) | {{TAX_PROVIDED}} | {{TAX_OUTSTANDING}} | {{TAX_DUE}} |

---

## Section D — Outputs of intake (system side-effects)

On completion + G4 sign-off, the filled questionnaire produces:

1. **Creatio matter record** populated with C1 contact + C3 financials + B routing decision
2. **`/api/matters` skeleton** at next available M-XXXX with `mode: production_placeholder` (or `production` post-DPA + first-data-transfer)
3. **Project folder structure** triggered (per [E] start-new-project script): `/Interlegal — Cyprus IP Box/Matters/<matter-id>/` in O365 with subfolders {{ ... }} (see [[scripts/start-new-project]] documentation)
4. **Track A/B routing** populated on `/calculator` for client preview if shared
5. **Required-evidence baseline JSON** generated from Section C8 — drives LLM doc-analyzer gap report (Sprint 1.7 module)
6. **G6 flag** on matter cockpit if Section C7 ticked any trigger

---

## Section E — Sign-offs + next steps

| Sign-off | Role | Name | Date |
|---|---|---|---|
| Section A screen verdict | Sales lead | {{SALES_LEAD_NAME}} | {{SECTION_A_DATE}} |
| Track routing (B) | Middle | {{SENIOR_NAME}} | {{SECTION_B_DATE}} |
| Discovery call complete (C) | Middle + AS | {{SENIOR_NAME}} + {{AS_NAME}} | {{SECTION_C_DATE}} |
| G4 engagement clearance | Engagement Partner (AS) | {{ENGAGEMENT_PARTNER_NAME}} | {{G4_DATE}} |
| S1 engagement letter signed | Client + AS | {{CLIENT_SIGNATORY}} + {{AS_NAME}} | {{S1_SIGN_DATE}} |

**Next steps:**

- Track A: proceed to Stage 2.1 IP fingerprinting (Junior) within 2 working days of G4 sign
- Track B: proceed to Phase 0 Stage 0.1 Existing Company Diagnostic (Middle + Cyprus partner) within 5 working days of G4 sign; S1 deferred until S0 verdict

---

## Quality gates (template instantiation checklist)

- **G1 — Author self-check.** Every `{{PLACEHOLDER}}` resolved or marked TBC with due date; hard blockers + G6 triggers ticked through all 7 + 9 items; substance baseline scored; sign-offs collected for Sections A + B at minimum.
- **G2 — Schema check.** Financial figures plausible (QE ≤ OE, OI > 0, currency consistent); engine pre-calc runs without schema error on Section C3 values.
- **G3 — Compliance / risk check.** AML re-check on client + UBOs run; sanctions screen on principals run; conflict register checked; all 7 hard blockers cleared or escalation route documented.
- **G4 — Engagement clearance.** AS reviews entire form + signs Section E G4 line; matter promoted from intake to active in Creatio + `/api/matters`; folder structure created in O365.

---

**Related:** [[stages]] Stage 1.1 + 1.2 source for 6-question screen + discovery template; [[01-engagement-letter-S2]] downstream contract; [[02-feasibility-opinion-S1]] downstream S1 output; [[03-ip-fingerprint-memo]] consumes Section C2; [[04-substance-gap-analysis]] consumes Section C4; [[15-existing-company-diagnostic]] consumes Section B + Track B branch; [[ADR-005]] G0-G6 gate model; [[ADR-007]] Track B existing-company; [[ADR-004]] substance + HARD_BLOCKERS; [[17-partner-verification-request]] separate flow for partner-side intake.